Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 949
Filter
1.
Chinese Journal of Pediatrics ; (12): 322-327, 2023.
Article in Chinese | WPRIM | ID: wpr-985870

ABSTRACT

Objective: To investigate the clinical characteristics and the risk factors of severe human metapneumovirus (hMPV)-associated community acquired pneumonia (CAP) in children. Methods: A retrospective case summary was conducted. From December 2020 to March 2022, 721 children who were diagnosed with CAP and tested positive for hMPV nucleic acid by PCR-capillary electrophoresis fragment analysis of nasopharyngeal secretions at the Yuying Children's Hospital, the Second Affiliated Hospital of Wenzhou Medical University were selected as the research objects. The clinical characteristics, epidemiological characteristics and mixed pathogens of the two groups were analyzed. According to CAP diagnostic criteria, the children were divided into the severe group and the mild group. Chi-square test or Mann-Whitney rank and contrast analysis was used for comparison between groups, while multivariate Logistic regression was applied to analyze the risk factors of the severe hMPV-associated CAP. Results: A total of 721 children who were diagnosed with hMPV-associated CAP were included in this study, with 397 males and 324 females. There were 154 cases in the severe group. The age of onset was 1.0 (0.9, 3.0) years, <3 years old 104 cases (67.5%), and the length of hospital stay was 7 (6, 9) days. In the severe group, 67 children (43.5%) were complicated with underlying diseases. In the severe group, 154 cases (100.0%) had cough, 148 cases (96.1%) had shortness of breath and pulmonary moist rales, and 132 cases (85.7%) had fever, 23 cases (14.9%) were complicated with respiratory failure. C-reactive protein (CRP) was elevated in 86 children (55.8%), including CRP≥50 mg/L in 33 children (21.4%). Co-infection was detected in 77 cases (50.0%) and 102 strains of pathogen were detected, 25 strains of rhinovirus, 17 strains of Mycoplasma pneumoniae, 15 strains of Streptococcus pneumoniae, 12 strains of Haemophilus influenzae and 10 strains of respiratory syncytial virus were detected. Six cases (3.9%) received heated and humidified high flow nasal cannula oxygen therapy, 15 cases (9.7%) were admitted to intensive care unit, and 2 cases (1.3%) received mechanical ventilation. In the severe group, 108 children were cured, 42 children were improved, 4 chlidren were discharged automatically without recovery and no death occurred. There were 567 cases in the mild group. The age of onset was 2.7 (1.0, 4.0) years, and the length of hospital stay was 4 (4, 6) days.Compared with the mild group, the proportion of children who age of disease onset <6 months, CRP≥50 mg/L, the proportions of preterm birth, congenital heart disease, malnutrition, congenital airway malformation, neuromuscular disease, mixed respiratory syncytial viruses infection were higher (20 cases (13.0%) vs. 31 cases (5.5%), 32 cases (20.8%) vs. 64 cases (11.3%), 23 cases (14.9%) vs. 44 cases (7.8%), 11 cases (7.1%) vs. 18 cases (3.2%), 9 cases (5.8%) vs. 6 cases (1.1%), 11 cases (7.1%) vs. 12 cases (2.1%), 8 cases (5.2%) vs. 4 cases (0.7%), 10 cases (6.5%) vs. 13 cases (2.3%), χ2=0.42, 9.45, 7.40, 4.94, 11.40, 8.35, 3.52, 6.92, all P<0.05). Multivariate Logistic regression analysis showed that age<6 months (OR=2.51, 95%CI 1.29-4.89), CRP≥50 mg/L (OR=2.20, 95%CI 1.36-3.57), prematurity (OR=2.19, 95%CI 1.26-3.81), malnutrition (OR=6.05, 95%CI 1.89-19.39) were the independent risk factors for severe hMPV-associated CAP. Conclusions: Severe hMPV-associated CAP is most likely to occur in infants under 3 years old and has a higher proportion of underlying diseases and co-infection. The main clinical manifestations are cough, shortness of breath and pulmonary moist rales, fever. The overall prognosis is good. Age<6 months, CRP≥50 mg/L, preterm birth, malnutrition are the independent risk factors for severe hMPV-associated CAP.


Subject(s)
Infant , Male , Female , Humans , Child , Infant, Newborn , Child, Preschool , Retrospective Studies , Cough , Coinfection , Premature Birth , Respiratory Sounds , Metapneumovirus , Pneumonia, Viral/epidemiology , Respiratory Syncytial Virus, Human , Community-Acquired Infections/epidemiology , Risk Factors , Dyspnea , Malnutrition
2.
Rev. méd. Chile ; 150(3): 316-323, mar. 2022. tab
Article in Spanish | LILACS | ID: biblio-1409804

ABSTRACT

BACKGROUND: In a decade, we faced two pandemic viruses, influenza A H1N1pdm09 and SARS CoV-2, whose most serious manifestation is pneumonia. AIM: To compare the clinical, epidemiological and management aspects of pneumonias caused by each pandemic virus in adults requiring hospitalization. Material and Methods: Comparative, observational study carried out at a regional Chilean hospital, including 75 patients with influenza A H1N1pdm09 prospectively studied in 2009 and 142 patients with SARS-CoV-2 studied in 2020. RESULTS: Patients with SARS-CoV-2 pneumonia were older (56 and 39.7 years respectively, p < 0.01) and had significantly more comorbidities. Cough, fever and myalgias were more frequent in influenza. Dyspnea was more frequent in COVID-19. Patients with COVID-19 had more extensive lung involvement and a longer hospitalization (13.6 and 8.6 days respectively, p = 0.01). There was no difference on ICU admission requirements and mortality attributable to pneumonia. Patients with influenza had greater APACHE scores and a higher frequency of a PaO2/FiO2 ratio ≤ 200. During COVID-19pandemic chest sean replaced x-ray examination. Also high-flow nasal cannulas and awake prone position ventilation were added as treatments. Conclusions: COVID-19 patients were older, had fewer classic flu symptoms but more dyspnea and longer hospitalization periods than patients with influenza.


Subject(s)
Humans , Adult , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Pneumonia, Viral/epidemiology , Influenza, Human/diagnosis , Influenza, Human/epidemiology , COVID-19/epidemiology , Dyspnea , Pandemics , SARS-CoV-2 , Hospitalization
3.
Cad. Saúde Pública (Online) ; 38(7): e00001022, 2022. tab, graf
Article in English | LILACS | ID: biblio-1384272

ABSTRACT

Off-label use of azithromycin, hydroxychloroquine, and ivermectin (the "COVID kit") has been suggested for COVID-19 treatment in Brazil without clinical or scientific evidence of efficacy. These drugs have known adverse drug reactions (ADR). This study aimed to analyze if the sales of drugs in the "COVID kit" are correlated to the reported number of ADR after the COVID-19 pandemic began. Data was obtained from the Brazilian Health Regulatory Agency (Anvisa) website on reported sales and ADRs for azithromycin, hydroxychloroquine, and ivermectin for all Brazilian states. The period from March 2019 to February 2020 (before the pandemic) was compared to that from March 2020 to February 2021 (during the pandemic). Trend adjustment was performed for time series data and cross-correlation analysis to investigate correlation between sales and ADR within the same month (lag 0) and in the following months (lag 1 and lag 2). Spearman's correlation coefficient was used to assess the magnitude of the correlations. After the pandemic onset, sales of all investigated drugs increased significantly (69.75% for azithromycin, 10,856,481.39% for hydroxychloroquine, and 12,291,129.32% for ivermectin). ADR levels of all medications but azithromycin were zero before the pandemic, but increased after its onset. Cross-correlation analysis was significant in lag 1 for all drugs nationwide. Spearman's correlation was moderate for azithromycin and hydroxychloroquine but absent for ivermectin. Data must be interpreted cautiously since no active search for ADR was performed. Our results show that the increased and indiscriminate use of "COVID kit" during the pandemic correlates to an increased occurrence of ADRs.


No Brasil, o uso off label de azitromicina, hidroxicloroquina e ivermectina (o "kit-COVID") foi sugerido para tratar COVID-19 sem que tivéssemos evidências clínicas ou científicas de sua eficácia. Estas drogas têm causado reações adversas (RA) em quem as tomam. Este estudo almejou analisar se a venda dos medicamentos que compõem o "kit-COVID" correlaciona-se com o número relatado de RAs após o início da pandemia da COVID-19. Os dados sobre vendas e RA associados a azitromicina, hidroxicloroquina e ivermectina foram obtidos no site da Agência Nacional de Vigilância Sanitária (Anvisa) para todos os estados brasileiros. Comparamos o período entre março de 2019 e fevereiro de 2020 (antes da pandemia) ao de março de 2020 a fevereiro de 2021 (durante a pandemia). Ajustamos tendências para os dados de séries temporais e as análises de correlação cruzada para investigar a correlação entre vendas e RA em um mesmo mês (lag 0) e nos seguintes (lag 1 e 2). O coeficiente de correlação de Spearman foi utilizado para avaliar a magnitude das correlações. Após o início da pandemia, as vendas de todos os medicamentos investigados aumentaram significativamente (69,75% para azitromicina, 10.856.481,39% para hidroxicloroquina e 12.291.129,32% para ivermectina). Os níveis de RAs de todos os medicamentos (com exceção de azitromicina) eram zero antes da pandemia mas aumentaram após seu início. A análise de correlação cruzada foi significativa no lag 1 para todas as drogas em todo o país. A correlação de Spearman foi moderada para azitromicina e hidroxicloroquina, mas ausente para ivermectina. Os dados devem ser interpretados com cautela, uma vez que não realizamos uma busca ativa por RA. Nossos resultados mostram que o uso aumentado e indiscriminado do "kit-COVID" durante a pandemia se correlaciona com uma ocorrência aumentada de RAs.


Se ha sugerido el uso fuera de lo establecido de azitromicina, hidroxicloroquina e ivermectina (el "kit-COVID") para el tratamiento de la COVID-19 en Brasil sin evidencia clínica o científica de su eficacia. Estos medicamentos tienen reacciones adversas (RAM) conocidas. Este estudio pretendía analizar si las ventas de medicamentos del "kit-COVID" están correlacionadas con el número de reacciones adversas notificadas tras el inicio de la pandemia de COVID-19. Los datos se obtuvieron del sitio web de la Agencia Nacional de Vigilancia Sanitaria (Anvisa) sobre las ventas y las RAM notificadas para la azitromicina, la hidroxicloroquina y la ivermectina para todos los estados brasileños. Se comparó el periodo de marzo de 2019 a febrero de 2020 (antes de la pandemia) con el de marzo de 2020 a febrero de 2021 (durante la pandemia). Se realizó un ajuste de tendencia para los datos de las series de tiempo y un análisis de correlación cruzada para investigar la correlación entre las ventas y la RAM dentro del mismo mes (lag 0) y en los meses siguientes (lag 1 y lag 2). Se utilizó el coeficiente de correlación de Spearman para evaluar la magnitud de las correlaciones. Tras el inicio de la pandemia, las ventas de todos los medicamentos investigados aumentaron significativamente (69,75% para la azitromicina, 10.856.481,39% para la hidroxicloroquina y 12.291.129,32% para la ivermectina). Los niveles de RAM de todos los medicamentos, excepto la azitromicina, eran nulos antes de la pandemia, pero aumentaron tras su inicio. El análisis de correlación cruzada fue significativo en el lag 1 para todos los medicamentos a nivel nacional. La correlación de Spearman fue moderada para la azitromicina y la hidroxicloroquina, pero no para la ivermectina. Los datos deben interpretarse con cautela, ya que no se realizó una búsqueda activa de RAM. Nuestros resultados muestran que el uso creciente e indiscriminado del "kit-COVID" durante la pandemia se correlaciona con una mayor aparición de las RAM.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Pneumonia, Viral/epidemiology , Coronavirus Infections/drug therapy , Coronavirus Infections/epidemiology , Drug-Related Side Effects and Adverse Reactions/epidemiology , COVID-19/drug therapy , Ivermectin/adverse effects , Brazil/epidemiology , Azithromycin/adverse effects , Pandemics , Hydroxychloroquine/adverse effects
4.
s.l; Organización Panamericana de la Salud; abr. 6, 2021. 31 p.
Non-conventional in Spanish | LILACS | ID: biblio-1152192

ABSTRACT

A la fecha, se reportan 4.329 pacientes (1,2%) en aislamiento domiciliario, 493 pacientes (0,1%) se encuentran hospitalizados (430 en sala general y 63 en Unidades de Cuidado Intensivo -UCI). Se informan 345.120 (96,9%) casos como recuperados


Subject(s)
Humans , Male , Female , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Panama/epidemiology
5.
Washington; Organización Panamericana de la Salud; abr. 07, 2021. 3 p.
Non-conventional in Spanish | LILACS | ID: biblio-1152295

ABSTRACT

El número de casos de COVID-19 sigue aumentando en toda la Región de las Américas. La semana pasada se notificaron más de 1,3 millones de casos nuevos y más de 37.000 muertes en nuestra Región. De hecho, más de la mitad de todas las muertes notificadas en el mundo en la última semana se produjeron en la Región de las Américas. Este dato nos recuerda el terrible costo humano de la pandemia.


Subject(s)
Humans , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Americas/epidemiology
6.
Washington; Organización Panamericana de la Salud; abr 14, 2021. 25 p.
Non-conventional in Spanish | LILACS | ID: biblio-1177781

ABSTRACT

Desde la actualización epidemiológica publicada por la OPS/OMS el 11 de marzo de 2021 hasta el 13 de abril de 2021, fueron notificados 6.182.423 casos confirmados adicionales de COVID-19, incluidas 161.007 defunciones en la región de las Américas, lo que representa un aumento de 11% de casos y de defunciones. Durante el mismo periodo, Bermuda, Bonaire, Curazao y Uruguay presentaron un incremento >50% en el número de casos y defunciones.


Subject(s)
Humans , Middle Aged , Aged , Aged, 80 and over , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Epidemiological Monitoring , Americas/epidemiology , Indigenous Peoples
7.
Washington; Organización Panamericana de la Salud; abr. 21, 2021. 39 p. ilus..
Non-conventional in Spanish | LILACS | ID: biblio-1178267

ABSTRACT

A la fecha, se reportan 3.689 pacientes (1,0%) en aislamiento domiciliario, 374 pacientes (0,1%) se encuentran hospitalizados (317 en sala general y 57 en Unidades de Cuidado Intensivo -UCI). Se informan 350.347 (97,2%) casos como recuperados.


Subject(s)
Humans , Male , Female , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Panama/epidemiology
8.
Washington; Organización Panamericana de la Salud; abr. 14, 2021. 10 p.
Non-conventional in English, Spanish | LILACS | ID: biblio-1178358

ABSTRACT

Esta herramienta está diseñada para realizar una evaluación rápida de las instituciones prestadoras de servicios de salud y de otras relacionadas con la salud y analiza su capacidad para recopilar datos críticos y de alta calidad en la respuesta a la pandemia de COVID-19. La herramienta evalúa el compromiso institucional con la pertinencia y la calidad de los datos utilizados para la toma de decisiones a todos los niveles. Además, facilita la autoevaluación para redefinir las prioridades de la pandemia; identifica la brecha de capacidad de los sistemas de datos internacionales, nacionales y subnacionales, y evalúa la capacidad para proporcionar datos fiables y constructivos.


This tool is designed for rapid assessment of health and health-related institutions and evaluates their capacity to gather critical, high-quality data in the COVID-19 pandemic response. The tool assesses institutional commitment to the timeliness and quality of data used for decision-making at all levels. It facilitates self-assessment to redefine pandemic priorities and, identifies the capacity gap within international, national, and subnational data systems, and assesses the ability to provide reliable and constructive data.


Subject(s)
Pneumonia, Viral/epidemiology , Data Collection/methods , Data Interpretation, Statistical , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Health Information Systems/statistics & numerical data
9.
Bogotá; Organización Panamericana de la Salud; abr. 20, 2021. 33 p. ilus..
Non-conventional in Spanish | LILACS | ID: biblio-1178359

ABSTRACT

Este es el reporte de situación COVID-19 Colombia No. 217 - 20 de abril de 2021.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/prevention & control , Colombia/epidemiology
10.
Bogotá; Organización Panamericana de la Salud; abr. 6, 2021. 30 p. ilus..
Non-conventional in Spanish | LILACS | ID: biblio-1178362

ABSTRACT

Este es el reporte de situación COVID-19 Colombia No. 215 - 06 de abril de 2021.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Colombia/epidemiology
11.
Bogotá; Organización Panamericana de la Salud; abr. 13, 2021. 23 p. ilus..
Non-conventional in Spanish | LILACS | ID: biblio-1178363

ABSTRACT

Este es el reporte de situación COVID-19 Colombia No. 216 - 13 de abril de 2021.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Colombia/epidemiology
13.
Bogotá; Organización Panamericana de la Salud; mar. 2, 2021. 31 p.
Non-conventional in Spanish | LILACS | ID: biblio-1151050

ABSTRACT

Este es el reporte de situación COVID-19 Colombia No. 210 - 02 de marzo de 2021.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Colombia/epidemiology
14.
Bogotá; Organización Panamericana de la Salud; mar. 9, 2021. 31 p.
Non-conventional in Spanish | LILACS | ID: biblio-1151051

ABSTRACT

Este es el reporte de situación COVID-19 Colombia No. 211- 09 de marzo de 2021.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Colombia/epidemiology
15.
Bogotá; Organización Panamericana de la Salud; mar. 16, 2021. 31 p.
Non-conventional in Spanish | LILACS | ID: biblio-1151052

ABSTRACT

Este es el reporte de situación COVID-19 Colombia No. 212 - 16 de marzo de 2021.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Colombia/epidemiology
16.
Washington; Organización Panamericana de la Salud; mar. 15, 2021. 7 p.
Non-conventional in Spanish | LILACS | ID: biblio-1151054

ABSTRACT

La crisis del COVID-19 representa una amenaza para todos los componentes del sistema alimentario, poniendo en riesgo el bienestar nutricional de las poblaciones de los países de América Latina y el Caribe. La crisis amenaza la disponibilidad de alimentos y el acceso físico y económico a alimentos de calidad, lo que lleva a un mayor consumo de productos ultraprocesados ​​o preenvasados ​​y cambia los patrones de consumo hacia dietas menos diversificadas. La COVID-19 presenta un mayor riesgo en personas con obesidad y otras enfermedades crónicas no transmisibles. Además, el acceso a los servicios relacionados con la nutrición, incluidos los exámenes de detección, el tratamiento y el asesoramiento, también está en riesgo en esta crisis. La OPS se ha unido al Fondo de las Naciones Unidas para la Infancia (UNICEF), la Organización para la Agricultura y la Alimentación (FAO) y el Programa Mundial de Alimentos (PMA) para emitir una "Declaración conjunta sobre nutrición en el contexto de la pandemia de COVID-19 - América Latina y el Caribe ", instando a todos los gobiernos, organizaciones de la sociedad civil y la comunidad de donantes a proteger y priorizar el estado nutricional de todas las personas. La Declaración establece cinco acciones principales recomendadas.


Subject(s)
Humans , Pneumonia, Viral/epidemiology , Poverty , Coronavirus Infections/epidemiology , Pandemics/prevention & control , Severe Acute Malnutrition/prevention & control , Social Protection in Health
17.
s.l; Organización Panamericana de la Salud; mar. 11, 2021. 5 p.
Non-conventional in Spanish | LILACS | ID: biblio-1151105

ABSTRACT

Reporte de Situación COVID-19 Cuba No. 48 (11 de enero de 2021).


Subject(s)
Humans , Male , Female , Aged , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Cuba/epidemiology
18.
s.l; Organización Panamericana de la Salud; mar. 11, 2021. 5 p.
Non-conventional in Spanish | LILACS | ID: biblio-1151106

ABSTRACT

Reporte de Situación COVID-19 Cuba No. 49 (18 de enero de 2021).


Subject(s)
Humans , Male , Female , Aged , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Cuba/epidemiology
19.
s.l; Organización Panamericana de la Salud; mar. 11, 2021. 5 p.
Non-conventional in Spanish | LILACS | ID: biblio-1151107

ABSTRACT

Reporte de Situación COVID-19 Cuba No. 50 (23 de enero de 2021).


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Cuba/epidemiology
20.
s.l; Organización Panamericana de la Salud; mar. 11, 2021. 5 p.
Non-conventional in Spanish | LILACS | ID: biblio-1151108

ABSTRACT

Reporte de Situación COVID-19 Cuba No. 51 (1 de febrero de 2021).


Subject(s)
Humans , Pneumonia, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Cuba/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL